scholarly journals An Oral Glucose Load Decreases Postprandial Extracellular Vesicles in Obese Adults with and without Prediabetes

Nutrients ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 580 ◽  
Author(s):  
Natalie Z. M. Eichner ◽  
Nicole M. Gilbertson ◽  
Luca Musante ◽  
Sabrina La Salvia ◽  
Arthur Weltman ◽  
...  

Although extracellular vesicles (EVs) are a novel biomediator of type 2 diabetes (T2D) and cardiovascular disease (CVD), the effects of hyperglycemia on EVs in humans is unknown. We tested the hypothesis that a 75-g oral glucose tolerance test (OGTT) would promote changes in EVs in relation to CVD risk. Twenty-five obese adults (Age: 52.4 ± 3.2 year, BMI: 32.5 ± 1.2 kg/m2) were screened for normal glucose tolerance (NGT, n = 8) and prediabetes (PD, n = 17) using American Diabetes Association criteria (75 g OGTT and/or HbA1c). Body composition (bioelectrical impedance) and fitness (VO2peak) were measured. Arterial stiffness (augmentation index; AIx) was measured at 0, 60- and 120-min while insulin, glucose, and free fatty acids were evaluated every 30 min during the OGTT to assess CVD risk. Annexin V positive (AV+) and Annexin V negative (AV-) total EVs, platelet EVs (CD31+/CD41+; CD41+), leukocyte EVs (CD45+; CD45+/CD41−), platelet endothelial cell adhesion molecule (PECAM) (CD31+) and endothelial EVs (CD 31+/CD41−; CD105+) were collected at 0 and 120 min. There were no differences in age, BMI, or body fat between NGT and PD (all P > 0.63). Total EVs, AV+ CD31+ (PECAM), and AV+ CD31+/CD41- (endothelial) EVs decreased after the OGTT (P ≤ 0.04). Circulating insulin at 2-h correlated with elevated post-prandial AV- CD45+ (r = 0.48, P = 0.04) while arterial stiffness related to reduced total EVs (r = −0.49, P = 0.03) and AV+CD41+ (platelet) (r = −0.52, P = 0.02). An oral glucose load lowers post-prandial total, platelet, and endothelial EVs in obese adults with NGT and prediabetes in relation to CVD risk.

2015 ◽  
Vol 17 (11) ◽  
pp. 1033-1041 ◽  
Author(s):  
K. Kaku ◽  
T. Kadowaki ◽  
Y. Terauchi ◽  
T. Okamoto ◽  
A. Sato ◽  
...  

Diabetes Care ◽  
2000 ◽  
Vol 23 (5) ◽  
pp. 710-712 ◽  
Author(s):  
Y. Tanaka ◽  
Y. Atsumi ◽  
K. Matsuoka ◽  
T. Onuma ◽  
R. Kawamori

2014 ◽  
Vol 106 (2) ◽  
pp. e25-e29 ◽  
Author(s):  
Toshihiro Matsuo ◽  
Yoshiki Kusunoki ◽  
Tomoyuki Katsuno ◽  
Takashi Ikawa ◽  
Takafumi Akagami ◽  
...  

1983 ◽  
Vol 104 (1) ◽  
pp. 85-90 ◽  
Author(s):  
X. Jeanrenaud ◽  
E. Maeder ◽  
E. Del Pozo ◽  
J. P. Felber

Abstract. The purpose of the present work was to study the effect of a methionine-enkephalin analogue (FK 33-824) on glucose tolerance in man. Groups of 5 to 8 normal subjects were given a 0.5 mg im injection of the drug or placebo just before a 100 g oral glucose load or a 0.5 g/kg iv glucose load. In the enkephalin analogue treated subjects, diminished insulin response to glucose was observed following the oral glucose load, with insulin values significantly lower than in the controls from time 10 to 90 min, but no corresponding change in the glucose curve. This effect was not observed when glucose was given iv in another group of 5 subjects in whom the significant blunting of the insulin response was accompanied by a significant decrease in glucose tolerance. These observations demonstrate that in man, enkephalin produces a decrease in insulin secretion in response to both oral and iv glucose loads. The absence of any marked impairment in glucose tolerance in the oral test in spite of the decreased insulin response suggests that enkephalin might have an additional effect in delaying glucose absorption.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1774-P
Author(s):  
NATALIE EICHNER ◽  
NICOLE M. GILBERTSON ◽  
LUCA MUSANTE ◽  
SABRINA LA SALVIA ◽  
EUGENE BARRETT ◽  
...  

2018 ◽  
Vol 51 ◽  
pp. 113-119 ◽  
Author(s):  
Ruoyun Ji ◽  
Jiahui Li ◽  
Ziying Yin ◽  
Yanqing Liu ◽  
Lizhuo Cang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document